China National Biotec Group (CNBG), a Sinopharm subsidiary, acquired China rights to an aesthetic gel implant from Boston’s Advanced Aesthetic Technologies (AAT) after making an equity investment in AAT. CNBG described the investment as a major but non-controlling stake. A CNBG subsidiary, Lanzhou Biotechnique Development, will be responsible for China regulatory approvals and for distributing Algeness®, the AAT gel product, in mainland China. Through Lanzhou, CNBG is the sole producer of botulinum toxin in China; its Hengli® (LANTOX) dominates the market with a 75% share.
Source: China Biotoday
